Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential ECF followed by DCF in HER2-negative advanced or metastatic gastric cancer
2010-019756-42Phase 2Terminated
- Sponsor
- Azienda Ospedaliera Universitaria Senese
- Start
- May 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epirubicin, cisplatin, fluorouracil and docetaxel in gastric cancer (GC), sponsored by Azienda Ospedaliera Universitaria Senese. Primary endpoint: Rate of patients free from disease progression after 6 months from treatment start. Started May 2011; status: terminated.
02
Drugs
epirubicincisplatinfluorouracildocetaxel
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on 2010-019756-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019756-42.